wHAT ARE PEOPLE SAYING ABOUT PEDS?
"There are lots of moving parts to PIPs/PSPs but with the right knowledge and support, that can be done in a way that supports drug development in pediatric oncology."
“The pediatric oncology community (academia, industry, regulatory, advocacy) is made up of a very special set of dedicated experts working diligently to improve pediatric drug development.”
“There are many people working very hard to figure out how to advance drugs for children. On the other hand, companies aren't really geared up for the process yet.”
“This was truly a one-of-a-kind effort that's invaluable to our community!”
“Collaboration/partnership/Communication. It's not anything revelatory, but the sessions reinforced the importance of these concepts across all of Peds Oncology development. The better and more efficient that industry, regulators and academia can be at working together, the faster that new and better drugs will become available for pediatric cancer patients.”
“I really wanted to thank the organizers for allowing for enough time for substantive discussions. The Q&A sessions were brilliant.”